The source body is too truncated to report the clinical substance accurately. The 8-K body provided cuts off after establishing that Tango Therapeutics filed a Regulation FD disclosure on October 23, 2026, announcing updated Phase 1/2 results for vopimetostat in combination with Revolution Medicines’ RAS(ON) inhibitors. The actual press release (Exhibit 99.1), which would contain the data, patient numbers, response rates, and any safety findings, is not included in the text provided.
Tango Therapeutics filed an 8-K on October 23, 2026, disclosing updated results from the ongoing Phase 1/2 trial of vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors, but the press release carrying the actual data was attached as a separate exhibit not included in the source provided here.
Without the exhibit, the specific efficacy numbers, patient counts, response rates, and safety signals that would anchor a meaningful clinical summary are not available. Reporting invented figures or inferring results from context would violate the accuracy standards governing this brief.
To publish a substantive article on this readout, please supply Exhibit 99.1 from the same 8-K filing, which contains the full updated dataset and any clinical commentary Tango released alongside it.
Source link: https://www.sec.gov/Archives/edgar/data/1819133/000119312526429423/d151613d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
